The hereby presented observation that CDK12 regulates PD-L1 mRNA variant expression and helps to dictate the balance of sPD-L1 relative to mPD-L1/exoPD-L1 brings CDK12 and CDK12 inhibitors into a novel immunotherapeutic context with relevance for NSCLC and other cancer types. Here, CDK12 is linked to cancer.